Equities analysts expect that Mateon Therapeutics Inc (NASDAQ:MATN) will report ($0.11) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for Mateon Therapeutics’ earnings. Mateon Therapeutics reported earnings of ($0.12) per share during the same quarter last year, which indicates a positive year over year growth rate of 8.3%. The firm is scheduled to announce its next quarterly earnings report on Monday, November 13th.

On average, analysts expect that Mateon Therapeutics will report full year earnings of ($0.42) per share for the current year. For the next year, analysts expect that the company will report earnings of ($0.50) per share. Zacks’ EPS averages are an average based on a survey of sell-side analysts that follow Mateon Therapeutics.

Mateon Therapeutics (NASDAQ:MATN) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.03.

A number of brokerages have recently commented on MATN. Maxim Group set a $2.00 price objective on Mateon Therapeutics and gave the company a “buy” rating in a research report on Thursday, April 27th. Roth Capital assumed coverage on Mateon Therapeutics in a report on Thursday, April 20th. They issued a “buy” rating and a $2.00 target price for the company. Finally, Zacks Investment Research lowered Mateon Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, May 13th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $2.00.

COPYRIGHT VIOLATION WARNING: This story was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/08/18/mateon-therapeutics-inc-matn-expected-to-announce-earnings-of-0-11-per-share.html.

Mateon Therapeutics (MATN) opened at 0.35955 on Friday. Mateon Therapeutics has a 12-month low of $0.27 and a 12-month high of $0.89. The firm’s market capitalization is $9.54 million. The stock has a 50 day moving average price of $0.34 and a 200-day moving average price of $0.53.

About Mateon Therapeutics

Mateon Therapeutics, Inc, formerly OXiGENE, Inc, is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT.

Get a free copy of the Zacks research report on Mateon Therapeutics (MATN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mateon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.